Pancreas cancer: Therapeutic trials in metastatic disease Review
| Authors: | Smithy, J. W.; O'Reilly, E. M. |
| Review Title: | Pancreas cancer: Therapeutic trials in metastatic disease |
| Abstract: | Metastatic pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer-related mortality in 2021. Cytotoxic therapies are the therapeutic mainstay for PDAC. The recent approval of olaparib as maintenance therapy for germline BRCA1/2-mutated PDAC and pembrolizumab for mismatch repair deficient PDAC represent molecularly targeted approaches for this disease. Investigational therapeutic strategies include targeting the stroma, metabolism, tumor microenvironment, and the immune system, and selected approaches are reviewed herein. © 2020 Wiley Periodicals LLC |
| Keywords: | genetics; pancreatic cancer; kras; clinical trials; metastatic disease |
| Journal Title: | Journal of Surgical Oncology |
| Volume: | 123 |
| Issue: | 6 |
| ISSN: | 0022-4790 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2021-01-01 |
| Start Page: | 1475 |
| End Page: | 1488 |
| Language: | English |
| DOI: | 10.1002/jso.26359 |
| PUBMED: | 33831245 |
| PROVIDER: | scopus |
| PMCID: | PMC8606164 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 3 May 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work